/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

eFFECTOR Therapeutics Inc.

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$0.155 -0.3256(-32.56%) EFTR at 04 Dec 2025 04:30 PM Biotechnology
Lowest Today 0.171
Highest Today 0.2376
Today’s Open 0.23
Prev. Close 0.2669
52 Week High 22.50
52 Week Low 0.17
Day’s Range: Low 0.171 High 0.2376
52-Week Range: Low 0.17 High 22.50
1 day return -
1 Week return -
1 month return -
3 month return -
6 month return -
1 year return -
3 year return -98.4
5 year return -
10 year return -

Institutional Holdings

Armistice Capital, LLC 4.74

The Carlyle Group Inc 4.10

StemPoint Capital LP 2.82

Vanguard Total Stock Mkt Idx Inv 2.74

Sectoral Asset Management Inc 2.03

Vanguard Group Inc 1.97

Ensign Peak Advisors Inc 0.70

Vanguard Institutional Extnd Mkt Idx Tr 0.53

Geode Capital Management, LLC 0.48

Fidelity Extended Market Index 0.29

Raymond James & Associates 0.26

Sea Otter Advisors LLC 0.22

Fidelity Total Market Index 0.06

Fidelity Series Total Market Index 0.05

Fidelity Nasdaq Composite Index 0.04

Morgan Stanley - Brokerage Accounts 0.03

Tower Research Capital LLC 0.03

NT Ext Equity Mkt Idx Fd - NL 0.03

Northern Trust Extended Eq Market Idx 0.03

NT Ext Equity Mkt Idx Fd - L 0.03

NT Ext Equity Mkt Idx Fd - DC - NL - T2 0.03

Spartan Extended Market Index Pool E 0.01

Royal Bank of Canada 0.01

ICA Group Wealth Management, LLC 0.01

Spartan Total Market Index Pool E 0.00

SSgA U.S. Extended Market Index Class I 0.00

State St US Extended Mkt Indx NL Cl C 0.00

Northern Trust Wilshire 5000 0.00

NT Ext Eq Mkt Indx Fd DC Lending Tier 5 0.00

JHVIT Total Stock Market Index I 0.00

SSgA U.S. Total Market Index Strategy 0.00

State St US Ttl Mkt Indx SL Cl I 0.00

BlackRock Extended Mkt Composite 0.00

Wells Fargo & Co 0.00

Qube Research & Technologies 0.00

Column Group LLC 0.00

EP Wealth Advisors, Inc. 0.00

Millennium Management LLC 0.00

Susquehanna International Group, LLP 0.00

We Are One Seven, LLC 0.00

Market Status

Strong Buy: 1

Buy: 1

Hold: 0

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 1.26 M

PB Ratio 13.3845

PE Ratio 0.0

Enterprise Value -3.88 M

Total Assets 20.54 M

Volume 1631337

Company Financials

Annual Revenue FY23:0 0.0M, FY22:0 0.0M, FY21:1430000 1.4M, FY20:42000000 42.0M, FY19:null 0.0M

Annual Profit FY23:null 0.0M, FY22:null 0.0M, FY21:1430000 1.4M, FY20:42000000 42.0M, FY19:null 0.0M

Annual Net worth FY23:-35941000 -35.9M, FY22:-12927000 -12.9M, FY21:15798000 15.8M, FY20:14211000 14.2M, FY19:null 0.0M

Quarterly Revenue Q1/2024:0 0.0M, Q4/2023:162000 0.2M, Q3/2023:0 0.0M, Q2/2023:0 0.0M, Q1/2023:0 0.0M

Quarterly Profit Q1/2024:-28000 -0.0M, Q4/2023:132000 0.1M, Q3/2023:null 0.0M, Q2/2023:null 0.0M, Q1/2023:null 0.0M

Quarterly Net worth Q1/2024:-8834000 -8.8M, Q4/2023:-9129000 -9.1M, Q3/2023:-8303000 -8.3M, Q2/2023:-8364000 -8.4M, Q1/2023:-9775000 -9.8M

Fund house & investment objective

Company Information eFFECTOR Therapeutics, Inc., a biopharmaceutical company, engages in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer. The company's lead product candidates comprise Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer; and Zotatifin, a small molecule inhibitor of eukaryotic initiation factor 4A (eIF4E), which is in Phase 1/2 clinical trial to treat patients with solid tumors, as well as completed Phase 2a open-label expansion cohort in combination with fulvestrant and abemaciclib to treat patients with ER+ breast cancer. The company has a research collaboration and license agreement with Pfizer Inc. to research and develop small molecules that target eIF4E; and collaboration agreement with the Dana-Farber Cancer Institute on a Phase 2 clinical trial, evaluating Zotatifin as combination treatment in ER+ endometrial cancer and in low grade serous ovarian cancer. eFFECTOR Therapeutics, Inc. was incorporated in 2012 and is headquartered in Solana Beach, California.

Organisation Biotechnology

Employees 14

Industry Biotechnology

CEO Dr. Stephen T. Worland Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow